Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232500 | 0.92 | ADAMTS5 (0.44) | ADAMTS5MMP2 | |
| SCHEMBL12232279 | 0.90 | GRIN2D (0.44) | ADAMTS5MMP2LRRK2LMNAMAPT | |
| SCHEMBL12232681 | 0.86 | MMP2 (0.42) | ADAMTS5MMP2MMP14LRRK2 | |
| SCHEMBL12232283 | 0.86 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12233840 | 0.86 | ADAMTS5 (0.51) | ADAMTS5MMP2MMP14ADAMTS4 | |
| SCHEMBL12233837 | 0.84 | ALDH1A1 (0.42) | ADAMTS5MMP2MMP14RAB9ASMN1; SMN2 | |
| SCHEMBL12232825 | 0.84 | MMP2 (0.46) | ADAMTS5MMP2MMP14NPC1RAB9A | |
| SCHEMBL12232459 | 0.83 | GRIN2D (0.53) | — | |
| SCHEMBL12233006 | 0.82 | LRRK2 (0.38) | LRRK2GFER | |
| SCHEMBL12233805 | 0.79 | GRIN1 (0.51) | ADAMTS5MMP2MMP14NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | GRIN2C, NR2C2, GRIN3A | ADAMTS5 4846/4885MMP2 4094/4885MMP14 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.